Nevro Corp is a global medical device company that specializes in developing innovative solutions for chronic pain management
The company focuses on providing advanced spinal cord stimulation systems designed to improve the quality of life for patients suffering from various types of neuropathic pain. With a commitment to research and development, Nevro aims to deliver cutting-edge technologies that enhance patient outcomes and address unmet medical needs in the field of pain relief. By pioneering therapies and treatment options, Nevro plays a crucial role in transforming how chronic pain is managed in clinical practice.
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSENVRO) to Globus Medical, Inc. NYSE: GMEDNYSEGMED)
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSENVRO) to Globus Medical for $5.85 per share is fair to Nevro shareholders.
Ademi & Fruchter LLP is investigating Nevro (NYSENVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSEGMED), a leading musculoskeletal solutions company, and Nevro Corp. NYSE: NVRONYSENVRO)
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Nevro stock rises as it gains CE Mark for its HFX iQ SCS system, the first with AI-based personalized pain relief. 2024 revenue outlook raised amid positive earnings.
